Drugmakers raise US prices on over 250 medicines
NEW YORK CITY, New York: At the start of 2025, drug companies raised prices on over 250 brand-name medications in the U.S., including Pfizer's COVID-19 treatment Paxlovid, Bristol Myers Squibb's ...
Over 250 medicines to cost more from January 1 in the U.S; is your critical drug in the list? Check here
More than 250 medications, including Paxlovid and cancer therapies, will see price increases in the United States beginning ...
Deccan Chronicle4d
Expiry of Rs 12k cr patented US drugs a big opportunity for pharma
The top 10 patented drugs getting expired in the coming years in the US, include Pembrolizumab, sold under the brand name ...
Pharmaceutical Technology6d
Ibrance by Pfizer for Metastatic Breast Cancer: Likelihood of Approval
Ibrance is under clinical development by Pfizer and currently in Phase III for Metastatic Breast Cancer. According to GlobalData, Phase III drugs for Metastatic Breast Cancer have a 44% phase ...
Pharmaceutical Technology6d
Ibrance by Pfizer for Rhabdomyosarcoma: Likelihood of Approval
Ibrance is under clinical development by Pfizer and currently in Phase II for Rhabdomyosarcoma. According to GlobalData, Phase II drugs for Rhabdomyosarcoma does not have sufficient historical data to ...
Health Rounds: Surgery may be unnecessary for common precancerous breast condition
Early results from a clinical trial appear to confirm that most women with the precancerous breast condition known as ductal ...
Scoop17d
Pharmac Consulting On Six Medicines For New Zealanders
The medicines are: Pharmac is also consulting on a price reduction and brand change for palbociclib used for advanced breast cancer, from Ibrance to Palbociclib Pfizer (supplied by the same supplier).
Press Gazette17d
Top 50 news websites in the world: AP and NBC see more than 50% monthly surge
President Donald Trump talks to the media at a public press event following the RNC debate in Houston, Texas in February 2016. Picture: Stock_photo_world/Shutterstock ...
precisionmedicineonline20d
Ibrance Plus Frontline Standard Therapy Delays Progression in HER2, HR-Positive Breast Cancer
SAN ANTONIO – Pfizer's CDK4/6 inhibitor Ibrance (palbociclib) added to standard anti-HER2 and endocrine therapy may become a new standard of care for frontline maintenance treatment of hormone ...
Yahoo Finance23d
SABCS: Pfizer’s IBRANCE combo improves PFS in breast cancer study
Healthcare giant Pfizer’s IBRANCE (palbociclib) as a combination therapy has improved progression-free survival from a Phase III trial in patients with metastatic breast cancer. Unveiled ...
clinicaltrialsarena23d
SABCS: Pfizer’s IBRANCE combo improves PFS in breast cancer study
Results found that IBRANCE was able to see medical profession free survival extended by an additional 15 months. Credit: Shutterstock / ShU studio Healthcare giant Pfizer’s IBRANCE (palbociclib) as a ...
Cancer Research23d
Palbociclib Dramatically Increases PFS in Metastatic Breast Cancer
The CDK4/6 inhibitor palbociclib (Ibrance; Pfizer) led to a significant improvement in progression-free survival (PFS) in patients with HR-positive, HER2-positive metastatic breast cancer when added ...